Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia 2019 (ICALL) /
Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia

17th - 19th May 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 859
Rating:

Prof Hervé Dombret, University Paris Diderot, Paris, France

Prof Hervé Dombret talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the use of tyrosine kinase inhibitors (TKIs) to treat Philadelphia chromosome-positive ALL.

He discusses the use of both transplantation as a more traditional method of treatment compared to the use of TKIs, in which he hopes will replace the use of chemotherapy and transplantation in the future.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation